Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06111027
Other study ID # STUDY00019659
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 20, 2023
Est. completion date October 20, 2024

Study information

Verified date October 2023
Source University of Minnesota
Contact Cagla Ozkul
Phone 612-624-4370
Email cozkul@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The general aim of the study is to provide evidence for usability and feasibility of applying vibro-tactile stimulation (VTS) at home as a non-invasive form of neuromodulation to improve speech in people with spasmodic dysphonia (SD). This work addresses a clinical need to develop alternative or auxiliary treatments for a rare voice disorder with very limited treatment options. Successful completion of the proposed work will be an important step in advancing laryngeal VTS as a therapeutic intervention for improving voice symptoms in SD.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 20, 2024
Est. primary completion date September 20, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of spasmodic dysphonia (laryngeal dystonia) for a minimum of 6 months with documented symptom relief after Botox injection. - Diagnosis is made by a voice disorder specialist. Exclusion Criteria: - Regular intake of benzodiazepines - Cognitive impairment: score < 27 on Mini-mental state examination - Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis

Study Design


Intervention

Device:
Vibro-tactile stimulation
Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perceived voice effort Participants will rate their perceived effort level of vocalization on an ordinal scale of 0 to 10 (0 being with no effort and 10 being with maximal effort). The recordings will provide subjective impression of treatment. 8 weeks
Secondary The number of voice breaks Prior to study begin, participants will receive a manual with instructions about the remote audio recording procedure. During pre- and post-application assessment, participants will record their voices using a voice recording application on their smartphone or digital tablet. The recordings will provide objective data on the number of voice breaks. 8 weeks
Secondary The duration of voice break Prior to study begin, participants will receive a manual with instructions about the remote audio recording procedure. During pre- and post-application assessment, participants will record their voices using a voice recording application on their smartphone or digital tablet. The recordings will provide objective data on the duration of voice breaks. 8 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT02061943 - Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change N/A
Recruiting NCT05158166 - DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia Phase 1/Phase 2
Recruiting NCT05580302 - Cortical Silent Period in Laryngeal Dystonia
Recruiting NCT05150106 - Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
Recruiting NCT05216770 - Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor Early Phase 1
Recruiting NCT05150093 - Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor N/A
Completed NCT00713414 - Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
Completed NCT01961297 - Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response Phase 2
Completed NCT00118586 - Neuropathology of Spasmodic Dysphonia
Not yet recruiting NCT04938154 - A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia Phase 2
Active, not recruiting NCT03292458 - Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Phase 2/Phase 3
Completed NCT02957942 - rTMS in Spasmodic Dysphonia N/A
Completed NCT02558634 - Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial N/A
Terminated NCT00895063 - Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia N/A
Completed NCT05158179 - Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia N/A
Enrolling by invitation NCT05892770 - Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia Phase 1/Phase 2
Recruiting NCT04648891 - Spasmodic Dysphonia Pain N/A
Completed NCT03042962 - Brain Networks in Dystonia
Not yet recruiting NCT06078527 - Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort N/A
Completed NCT03746509 - Laryngeal Vibration for Spasmodic Dysphonia N/A